Knight Therapeutics Inc. announced that it has appointed Jeffrey Kadanoff as its Chief Financial Officer. Prior to joining Knight, Mr. Kadanoff was a Principal with Bain & Company where he served as a strategy consultant for 14 years. Additionally, Mr. Kadanoff was Vice President-Strategic Planning and Development at Reitmans.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
6 CAD | 0.00% | -1.80% | +15.61% |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+15.61% | 445M | |
+16.17% | 79.16B | |
+8.27% | 8.72B | |
-16.43% | 4.79B | |
+48.34% | 4.62B | |
+2.91% | 3.82B | |
+14.51% | 2.33B | |
-26.94% | 2.2B | |
+16.55% | 2.1B | |
-36.25% | 2.04B |
- Stock Market
- Equities
- GUD Stock
- News Knight Therapeutics Inc.
- Knight Therapeutics Inc. Appoints Jeffrey Kadanoff as New CFO